Search

Your search keyword '"Hagemeister, Fredrick B."' showing total 315 results
Start Over Author "Hagemeister, Fredrick B." Language english
315 results on '"Hagemeister, Fredrick B."'

1. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial

Author

Gurumurthi, Ashwath, Chin, Collin K., Feng, Lei, Fowler, Nathan H., Strati, Paolo, Hagemeister, Fredrick B., Fayad, Luis E., Westin, Jason R., Obi, Chizobam, Arafat, Janine, Nair, Ranjit, Steiner, Raphael E., Neelapu, Sattva S., Flowers, Christopher R., and Nastoupil, Loretta J.

Published
2024
Full Text
View/download PDF

3. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

Author

Marques-Piubelli, Mario L., Parra, Edwin R., Feng, Lei, Soto, Luisa Solis, Gallardo, Mariana, Gouni, Sushanth, Samaniego, Felipe, Noorani, Mansoor, Hagemeister, Fredrick B., Westin, Jason R., Lee, Hun Ju, Rodriguez, Maria A., Neelapu, Sattva S., Gunther, Jillian R., Fowler, Nathan H., Flowers, Christopher R., Wistuba, Ignacio I., Nastoupil, Loretta J., Vega, Francisco, and Strati, Paolo

Published
2022
Full Text
View/download PDF

4. Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

Author

Wang, Michael L, Jain, Preetesh, Zhao, Shuangtao, Lee, Hun Ju, Nastoupil, Loretta, Fayad, Luis, Ok, Chi Young, Kanagal-Shamanna, Rashmi, Hill, Holly A, Yao, Yixin, Hagemeister, Fredrick B, Westin, Jason R, Fowler, Nathan, Samaniego, Felipe, Steiner, Raphael, Nair, Ranjit, Iyer, Swaminathan P, Navsaria, Lucy, Badillo, Maria, Feng, Lei, Xuelin, Huang, Nogueras Gonzalez, Graciela M, Xu, Guofan, Wagner-Bartak, Nicolaus, Thirumurthi, Selvi, Santos, David, Tang, Guilin, Lin, Pei, Wang, Sa A, Jorgensen, Jeff, Yin, C Cameron, Li, Shaoying, Patel, Keyur P, Vega, Francisco, Medeiros, L Jeffery, Flowers, Christopher R, and Wang, Linghua

Published
2022
Full Text
View/download PDF

6. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

Author

Strati, Paolo, Nastoupil, Loretta J., Westin, Jason, Fayad, Luis E., Ahmed, Sairah, Fowler, Nathan H., Hagemeister, Fredrick B., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Adkins, Sherry, Claussen, Catherine M., Martinez, Charles S., Hawkins, Misha C., Johnson, Nicole A., Singh, Prachee, Mistry, Haleigh E., Horowitz, Sandra, George, Shirley, Feng, Lei, Kebriaei, Partow, Shpall, Elizabeth J., Neelapu, Sattva S., Tummala, Sudhakar, and Chi, T. Linda

Published
2020
Full Text
View/download PDF

7. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL

Author

Xu-Monette, Zijun Y., Zhang, Hongwei, Zhu, Feng, Tzankov, Alexandar, Bhagat, Govind, Visco, Carlo, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., You, Hua, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, AndrésJ.M., Møller, Michael B., Parsons, Benjamin M., van Krieken, J. Han, Piris, Miguel A., Winter, Jane N., Hagemeister, Fredrick B., Shahbaba, Babak, De Dios, Ivan, Zhang, Hong, Li, Yong, Xu, Bing, Albitar, Maher, and Young, Ken H.

Published
2020
Full Text
View/download PDF

8. Can we cure refractory Hodgkin’s lymphoma with transplantation?

Author

Ciurea, Stefan O., Kongtim, Piyanuch, Srour, Samer, Saini, Neeraj, Im, Jin, Ramdial, Jeremy, Khouri, Issa, Anderlini, Paolo, Popat, Uday, Hosing, Chitra, Champlin, Richard E., Lee, Hun J., Fayad, Luis E., Hagemeister, Fredrick B., Bica, Ana M., Lipan, Lavinia, Craciun, Oana, Jercan, Cristina G., Tanase, Alina, and Colita, Anca

Published
2021
Full Text
View/download PDF

9. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

Author

Albitar, Maher, Zhang, Hong, Goy, Andre, Xu-Monette, Zijun Y., Bhagat, Govind, Visco, Carlo, Tzankov, Alexandar, Fang, Xiaosheng, Zhu, Feng, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Hagemeister, Fredrick B., Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J. M., Møller, Michael B., Parsons, Benjamin M., van Krieken, J. Han, Piris, Miguel A., Winter, Jane N., Li, Yong, Xu, Bing, and Young, Ken H.

Published
2022
Full Text
View/download PDF

10. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.

Author

Gordon, Max J., Feng, Lei, Strati, Paolo, Lee, Hun Ju, Hagemeister, Fredrick B., Westin, Jason R., Samaniego, Felipe, Marques‐Piubelli, Mario L., Vega Vazquez, Francisco, Parra Cuentas, Edwin R., Solis‐Soto, Luisa M., Ma, Wencai, Wang, Jing, Claret, Linda, Averill, Barbara, Ibanez, Karina, Fayad, Luis E., Flowers, Christopher R., Green, Michael R., and Davis, R. Eric

Subjects
MUCOSA-associated lymphoid tissue lymphoma, LENALIDOMIDE, BRUTON tyrosine kinase, RITUXIMAB, FOLLICULAR lymphoma
Abstract

Background: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent non‐Hodgkin lymphomas (iNHL). Median survival for iNHL is approximately 20 years. Because standard treatments are not curative, patients often receive multiple lines of therapy with associated toxicity—rationally designed, combination therapies with curative potential are needed. The immunomodulatory drug lenalidomide was evaluated in combination with rituximab for the frontline treatment of FL in the phase 3 RELEVANCE study. Ibrutinib, an oral Bruton tyrosine kinase inhibitor, is active in NHL and was evaluated in combination with lenalidomide, rituximab, and ibrutinib (IRR) in a phase 1 study. Methods: The authors conducted an open‐label, phase 2 clinical trial of IRR for previously untreated FL and MZL. The primary end point was progression‐free survival (PFS) at 24 months. Results: This study included 48 participants with previously untreated FL grade 1–3a (N = 38), or MZL (N = 10). Participants received 12, 28‐day cycles of lenalidomide (15 mg, days 1–21 cycle 1; 20 mg, cycles 2–12), rituximab (375 mg/m2 weekly in cycle 1; day 1 cycles 2‐12), and ibrutinib 560 mg daily. With a median follow‐up of 65.3 months, the estimated PFS at 24 months was 78.8% (95% confidence interval [CI], 68.0%–91.4%) and 60‐month PFS was 59.7% (95% CI, 46.6%–76.4%). One death occurred unrelated to disease progression. Grade 3–4 adverse events were observed in 64.6%, including 50% with grade 3–4 rash. Conclusions: IRR is highly active as frontline therapy for FL and MZL. Compared to historical results with lenalidomide and rituximab, PFS is similar with higher grade 3–4 toxicity, particularly rash. The study was registered with ClinicalTrials.gov (NCT02532257). After 5 years of follow‐up from a phase 2 clinical trial of ibrutinib, lenalidomide, and rituximab in previously untreated patients with follicular and marginal zone lymphoma, the 5‐year progression‐free survival rate was 59.7% and the overall survival rate was 97.9%. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review

Author

Pinnix, Chelsea C., Shah, Jatin J., Chuang, Hubert, Costelloe, Colleen M., Medeiros, L. Jeffrey, Wogan, Christine F., Reed, Valerie, Smith, Grace L., Milgrom, Sarah, Patel, Krina, Huo, Jinhai, Turturro, Francesco, Romaguera, Jorge, Fayad, Luis, Oki, Yasuhiro, Fanale, Michelle A., Westin, Jason, Nastoupil, Loretta, Hagemeister, Fredrick B., Rodriguez, Alma, Qazilbash, Muzaffar, Shah, Nina, Bashir, Qaiser, Ahmed, Sairah, Nieto, Yago, Hosing, Chitra, Rohren, Eric, and Dabaja, Bouthaina

Published
2016
Full Text
View/download PDF

15. Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma

Author

Pinnix, Chelsea C., Smith, Grace L., Milgrom, Sarah, Osborne, Eleanor M., Reddy, Jay P., Akhtari, Mani, Reed, Valerie, Arzu, Isidora, Allen, Pamela K., Wogan, Christine F., Fanale, Michele A., Oki, Yasuhiro, Turturro, Francesco, Romaguera, Jorge, Fayad, Luis, Fowler, Nathan, Westin, Jason, Nastoupil, Loretta, Hagemeister, Fredrick B., Rodriguez, M. Alma, Ahmed, Sairah, Nieto, Yago, and Dabaja, Bouthaina

Published
2015
Full Text
View/download PDF

16. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial

Author

Oki, Yasuhiro, Ewer, Michael S., Lenihan, Daniel J., Fisch, Michael J., Hagemeister, Fredrick B., Fanale, Michelle, Romaguera, Jorge, Pro, Barbara, Fowler, Nathan, Younes, Anas, Astrow, Alan B., Huang, Xuelin, Kwak, Larry W., Samaniego, Felipe, McLaughlin, Peter, Neelapu, Sattva S., Wang, Michael, Fayad, Luis E., Durand, Jean-Bernard, and Alma Rodriguez, M.

Published
2015
Full Text
View/download PDF

17. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential

Author

Li, Yong, Xu-Monette, Zijun Y., Abramson, Jeremy, Sohani, Aliyah R., Bhagat, Govind, Tzankov, Alexandar, Visco, Carlo, Zhang, Shanxiang, Dybkaer, Karen, Pan, Zenggang, Xu, Min, Tam, Wayne, Zu, Youli, Hsi, Eric D., Hagemeister, Fredrick B., Go, Heounjeong, van Krieken, J. Han, Winter, Jane N., Ponzoni, Maurilio, Ferreri, Andrés J. M., Møller, Michael B., Piris, Miguel A., Wang, Yingjun, Zhang, Mingzhi, and Young, Ken H.

Published
2023
Full Text
View/download PDF

18. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Author

Fowler, Nathan H, Davis, R Eric, Rawal, Seema, Nastoupil, Loretta, Hagemeister, Fredrick B, McLaughlin, Peter, Kwak, Larry W, Romaguera, Jorge E, Fanale, Michelle A, Fayad, Luis E, Westin, Jason R, Shah, Jatin, Orlowski, Robert Z, Wang, Michael, Turturro, Francesco, Oki, Yasuhiro, Claret, Linda C, Feng, Lei, Baladandayuthapani, Veerabhadran, Muzzafar, Tariq, Tsai, Kenneth Y, Samaniego, Felipe, and Neelapu, Sattva S

Published
2014
Full Text
View/download PDF

19. Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation

Author

Dabaja, Bouthaina S., Hess, Kenneth, Shihadeh, Ferial, Podoloff, Donald A., Medeiros, L. Jeffrey, Mawlawi, Osama, Arzu, Isidora, Oki, Yasuhiro, Hagemeister, Fredrick B., Fayad, Luis E., Reed, Valerie K., Kedir, Aziza, Wogan, Christine F., and Rodriguez, Alma

Published
2014
Full Text
View/download PDF

21. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL

Author

Nair, Ranjit, Ayers, Amy, Nastoupil, Loretta J., Gunther, Jillian R., Fayad, Luis, Fowler, Nathan H., Miranda, Roberto N., Hagemeister, Fredrick B., Lee, Hun Ju, Rodriguez, Maria Alma, Steiner, Raphael, Strati, Paolo, Nieto, Yago, Ramdial, Jeremy L., Chihara, Dai, Wang, Michael L., Malpica Castillo, Luis E, Saini, Neeraj, Jain, Preetesh, Pinnix, Chelsea C., Dabaja, Bouthaina S., Green, Michael R, Flowers, Christopher R., Medeiros, L. Jeffrey, Marques-Piubelli, Mario L., Vega, Francisco, Noorani, Mansoor, Ahmed, Sairah, Westin, Jason, Neelapu, Sattva S., Feng, Lei, and Iyer, Swaminathan Padmanabhan

Published
2022
Full Text
View/download PDF

22. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial

Author

Westin, Jason R., Thompson, Michael A., Cataldo, Vince D., Fayad, Luis E., Fowler, Nathan, Fanale, Michelle A., Neelapu, Saatva, Samaniego, Felipe, Romaguera, Jorge, Shah, Jatin, McLaughlin, Peter, Pro, Barbara, Kwak, Larry W., Sanjorjo, Perpetua, Murphy, William A., Jimenez, Camillo, Toth, Bela, Dong, Wenli, and Hagemeister, Fredrick B.

Published
2013
Full Text
View/download PDF

26. The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma

Author

Chihara, Dai, Fanale, Michelle A., Miranda, Roberto N., Noorani, Mansoor, Westin, Jason R., Nastoupil, Loretta J., Hagemeister, Fredrick B., Fayad, Luis E., Romaguera, Jorge E., Samaniego, Felipe, Turturro, Francesco, Lee, Hun J., Neelapu, Sattva S., Rodriguez, M. Alma, Wang, Michael, Fowler, Nathan H., Davis, Richard E., Medeiros, L. Jeffrey, Hosing, Chitra, Nieto, Yago L., and Oki, Yasuhiro

Published
2017
Full Text
View/download PDF

27. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma.

Author

Steiner, Raphael E., Parra, Edwin R., Vega, Francisco, Feng, Lei, Westin, Jason R., Neelapu, Sattva S., Strati, Paolo, Green, Michael R., Flowers, Christopher R., Solis, Luisa M., Wistuba, Ignacio I., Ahmed, Sairah, Nair, Ranjit, Hagemeister, Fredrick B., Noorani, Mansoor, and Marques-Piubelli, Mario L.

Subjects
MACROPHAGES, PROGNOSIS, THYMUS tumors, NON-Hodgkin's lymphoma, LYMPHOMAS, DISEASE relapse
Abstract

Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory microenvironment. Although most patients can be cured with standard-of-care immunochemotherapy, patients who have disease relapse have an unfavorable prognosis. Pre-treatment prognostic biomarkers in PMBCL are needed. In this retrospective study, we analyzed the clinical features and outcomes of PMBCL patients and their association with immune cell subpopulations identified by multiplex immunofluorescence at initial diagnosis. Two different antibody panels were used to assess macrophages in tissue biopsy specimens collected before the initiation of induction therapy. Twelve PMBCL patients, including five patients who had disease relapse, were included in the analysis. At a median follow-up time of 32.2 months, the median progression-free and overall survival durations were not reached. Our findings suggest that a high density of PD-L1+ macrophages is associated with favorable features, such as early disease stage and the absence of B-symptoms, and indicate that a high percentage of PD-L1+ macrophages and high densities of CD30+PD-L1+ cells and CD30+ cells might be associated with a lower risk of relapse within 12 months of therapy initiation. Further studies are needed to develop a biomarker signature predictive of treatment response with therapeutic consequences for patients with newly diagnosed PMBCL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center

Author

Chihara, Dai, Cheah, Chan Y., Westin, Jason R., Fayad, Luis E., Rodriguez, Maria A., Hagemeister, Fredrick B., Pro, Barbara, McLaughlin, Peter, Younes, Anas, Samaniego, Felipe, Goy, Andre, Cabanillas, Fernando, Kantarjian, Hagop, Kwak, Larry W., Wang, Michael L., and Romaguera, Jorge E.

Published
2016
Full Text
View/download PDF

30. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

Author

Takahashi, Koichi, Sivina, Mariela, Hoellenriegel, Julia, Oki, Yasuhiro, Hagemeister, Fredrick B., Fayad, Luis, Romaguera, Jorge E., Fowler, Nathan, Fanale, Michelle A., Kwak, Larry W., Samaniego, Felipe, Neelapu, Sattva, Xiao, Lianchun, Huang, Xuelin, Kantarjian, Hagop, Keating, Michael J., Wierda, William, Fu, Kai, Chan, Wing C., Vose, Julie M., OʼBrien, Susan, Davis, Richard E., and Burger, Jan A.

Published
2015
Full Text
View/download PDF

35. Double hit lymphoma: the MD Anderson Cancer Center clinical experience

Author

Oki, Yasuhiro, Noorani, Mansoor, Lin, Pei, Davis, Richard E., Neelapu, Sattva S., Ma, Long, Ahmed, Mohamed, Rodriguez, Maria Alma, Hagemeister, Fredrick B., Fowler, Nathan, Wang, Michael, Fanale, Michelle A., Nastoupil, Loretta, Samaniego, Felipe, Lee, Hun J., Dabaja, Bouthaina S., Pinnix, Chelsea C., Medeiros, Leonard J., Nieto, Yago, Khouri, Issa, Kwak, Larry W., Turturro, Francesco, Romaguera, Jorge E., Fayad, Luis E., and Westin, Jason R.

Published
2014
Full Text
View/download PDF

36. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

Author

Oki, Yasuhiro, Westin, Jason R., Vega, Francisco, Chuang, Hubert, Fowler, Nathan, Neelapu, Sattva, Hagemeister, Fredrick B., McLaughlin, Peter, Kwak, Larry W., Romaguera, Jorge E., Fanale, Michelle, Younes, Anas, Rodriguez, Maria Alma, Orlowski, Robert Z., Wang, Michael, Ouzounian, Souzanne T., Samaniego, Felipe, and Fayad, Luis

Published
2013
Full Text
View/download PDF

39. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

Author

Romaguera, Jorge E., Fayad, Luis E., Feng, Lei, Hartig, Kimberly, Weaver, Pamela, Rodriguez, Maria Alma, Hagemeister, Fredrick B., Pro, Barbara, McLaughlin, Peter, Younes, Anas, Samaniego, Felipe, Goy, Andre, Cabanillas, Fernando, Kantarjian, Hagop, Kwak, Larry, and Wang, Michael

Published
2010
Full Text
View/download PDF

40. Incidence and risk factors of venous thromboembolic events in lymphoma

Author

Zhou, Xiao, Teegala, Shyam, Huen, Auris, Ji, Yuan, Fayad, Luis, Hagemeister, Fredrick B., Gladish, Gregory, and Vadhan-Raj, Saroj

Subjects
Venous thrombosis -- Risk factors, Venous thrombosis -- Research, Lymphomas -- Research, Health, Health care industry
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjmed.2010.05.021 Byline: Xiao Zhou (a), Shyam Teegala (a), Auris Huen (a), Yuan Ji (b), Luis Fayad (c), Fredrick B. Hagemeister (c), Gregory Gladish (c), Saroj Vadhan-Raj (a)(c) Keywords: Cancer; Lymphoma; Risk factor; Thrombosis Abstract: Cancer patients are at increased risk of venous thromboembolism; however, the incidence and risk factors for venous thromboembolism in lymphoma patients are not well defined. Author Affiliation: (a) Department of Sarcoma Medical Oncology, Section of Cytokines & Supportive Oncology, The University of Texas MD Anderson Cancer Center, Houston (b) Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston (c) Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston Article Note: (footnote) Funding: Clinical research funding., Conflict of Interest: The authors indicated no potential conflicts of interest., Authorship: Saroj Vadhan-Raj, the principal investigator, was responsible for conception and design, execution of the study, analysis and interpretation of the data, and drafting of the article. Xiao Zhou, Shyam Teegala, and Auris Huen assisted with the writing of the protocol and manuscript, coordinated the collection and the statistical analysis of the data and critical review of the article. Yuan Ji was responsible for the statistical analysis and the interpretation of the results. Luis Fayad and Fredrick B. Hagemeister provided the study participants and critically reviewed the article, and Gregory Gladish provided radiologic expertise and critically reviewed the article.

Published
2010

48. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

Author

Thomas, Deborah A., Faderl, Stefan, OʼBrien, Susan, Bueso-Ramos, Carlos, Cortes, Jorge, Garcia-Manero, Guillermo, Giles, Francis J., Verstovsek, Srdan, Wierda, William G., Pierce, Sherry A., Shan, Jianqin, Brandt, Mark, Hagemeister, Fredrick B., Keating, Michael J., Cabanillas, Fernando, and Kantarjian, Hagop

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results